Back to search
Aggressive Systemic Mastocytosis (ASM)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Aggressive Systemic Mastocytosis (ASM) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Aggressive Systemic Mastocytosis (ASM) trials you may qualify forThis is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patient…
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsore…
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mast…
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (Ad…
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well th…